Shuai Wang

Dr. Shuai Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
WCWujun Chen
Wujun Chen
SZShun Zhang
Shun Zhang
JWJianfeng Wu
Jianfeng Wu
TYTing Ye
Ting Ye
SWShuai Wang
Shuai Wang
DXDongming Xing
Dongming Xing

1 July 2021 in Clinica Chimica Acta
Verified
Journal Article
Closed access
WCWujun Chen
Wujun Chen
LLLu Li
Lu Li
JWJie Wang
Jie Wang
RZRenshuai Zhang
Renshuai Zhang
TZTingting Zhang
Tingting Zhang
DXDongming Xing
Dongming Xing

30 September 2021 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
WCWujun Chen
Wujun Chen
YZYingjie Zhong
Yingjie Zhong
NFNuan Feng
Nuan Feng
ZGZhu Guo
Zhu Guo
SWShuai Wang
Shuai Wang
DXDongming Xing
Dongming Xing
Age-related cardiovascular disease is the leading cause of death in elderly populations. Coxibs, including celecoxib, valdecoxib, etoricoxib, parecoxib, lumiracoxib, and rofecoxib, are selective cyclooxygenase-2 (COX-2) inhibitors used to treat osteoarthritis and rheumatoid arthritis. However, many coxibs have been discontinued due to adverse cardiovascular events. COX-2 contains cyclooxygenase (COX) and peroxidase (POX) sites. COX-2 inhibitors block COX activity without affecting POX activity. Recently, quercetin-like flavonoid compounds with OH groups in their B-rings have been found to serve as activators of COX-2 by binding the POX site. Galangin-like flavonol compounds serve as inhibitors of COX-2. Interestingly, nabumetone, flurbiprofen axetil, piketoprofen-amide, and nepafenac are ester prodrugs that inhibit COX-2. The combination of galangin-like flavonol compounds with these prodrug metabolites may lead to the development of novel COX-2 inhibitors. This review focuses on the most compelling evidence regarding the role and mechanism of COX-2 in cardiovascular diseases and demonstrates that quercetin-like compounds exert potential cardioprotective effects by serving as cofactors of COX-2.

1 June 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
WCWujun Chen
Wujun Chen
YWYudong Wu
Yudong Wu
QLQi Lu
Qi Lu
SWShuai Wang
Shuai Wang
DXDongming Xing
Dongming Xing

10 August 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
SDSihan Du
Sihan Du
YLYing Liu
Ying Liu
YYYuan Yuan
Yuan Yuan
YWYuran Wang
Yuran Wang
YCYanfang Chen
Yanfang Chen
YCYuhua Chi
Yuhua Chi
The 70 kDa heat shock protein (HSP70) is one of the most conserved proteins and a ubiquitous molecular chaperone that plays a role in the folding, remodeling, and degradation of various proteins to maintain proteostasis. It has been shown that HSP70 is abundantly expressed in cancer and enhances tumor resistance to radiotherapy by inhibiting multiple apoptotic pathways, such as interfering with the cellular senescence program, promoting angiogenesis, and supporting metastasis. Thus, HSP70 provides an effective target for enhancing the effects of radiation therapy in the clinical management of cancer patients. Inhibition of HSP70 enhances the radiation-induced tumor-killing effect and thus improves the efficacy of radiotherapy. This article reviews the sensitivity of Hsp70 and its related inhibitors to radiotherapy of tumor cells.

1 December 2021 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
WCWujun Chen
Wujun Chen
JXJiyao Xing
Jiyao Xing
XLXinlin Liu
Xinlin Liu
SWShuai Wang
Shuai Wang
DXDongming Xing
Dongming Xing